[DanBC]

> You can do the NHS way and forbid paying for unwarranted procedures for life extension.

Please cite which of these procedures are forbidden.

> NHS adopts this measures in the so called death panels

The US has these too, in the form of insurance companies.

I think if you're going to have them it's better to ahve them be publically owned not for profit organisations under intense government regulation, rather than profit making companies.

[cjalmeida]

NHS guidelines is to not extend a terminal patient's life indefinitely. Not sure the explicitly reason is costs but having people months on intensive care is pretty darn expensive

http://www.telegraph.co.uk/news/health/news/6127514/Sentence...

Also, it had a policy of not funding what they call "procedures of limited clinical value"

http://www.miltonkeynesccg.nhs.uk/referrals-and-priorities-p...

[DanBC]

Your first link refers to the Liverpool Care Pathway. This was only for people with end stage terminal illness. It doesn't happen anymore -- the Liverpool Care Pathway has been stopped in all hospitals in England.

https://www.compassionindying.org.uk/wp-content/uploads/2015...

https://www.theguardian.com/society/2013/jul/15/liverpool-ca...

Your second link is even weirder. Firstly you've linked to a local organisation that covers a population of 250,000 people. Milton Keynes CCG is not a national organisaton. Secondly, you've said this is about not funding some treatments, but you've linked to the page where people can request funding for those treatments. Thirdly, You think US insurance companies fund anything and everything?

Some treatments are very expensive and also do not work. We see this most commonly with cancer drugs. To ease the burden for CCGs there's a national "Cancer Drugs Fund", set up to provide access to the latest cancer drugs.

They do not work. They do not work, and they cause harm, and they are very expensive.

https://www.theguardian.com/science/2017/apr/28/cancer-drugs...

> The Cancer Drugs Fund, set up by the government to pay for expensive medicines that the NHS would not normally finance, failed to benefit patients and may have resulted in some of them suffering unnecessarily from toxic side-effects, experts say.

> An analysis in a leading cancer journal has found that the fund paid out £1.27bn from 2010 to 2016 – an amount that would have paid for an entire year of mainstream cancer drugs for the NHS.

> But medicine it paid for was not worth the money, the report concluded. The analysis in the Annals of Oncology journal looked at 29 cancer drugs approved for 47 different types of treatment (known as indications), some of which were approved to treat more than one cancer. They found that only 18 of the 47 treatments prolonged the patient’s life, and then only by an average of three months.

But assuming someone still wants it, and they apply for individual funding and don't get it, they're now in the same position as many Americans: they can crowd-fund and go private.